Evidence map›Paper›PMID 31977013›Full record

ArticleCardiovascular research2020

Impact of functional studies on exome sequence variant interpretation in early-onset cardiac conduction system diseases.

Kenshi Hayashi, Ryota Teramoto, Akihiro Nomura, Yoshihiro Asano, Manu Beerens, Yasutaka Kurata, Isao Kobayashi, Noboru Fujino, Hiroshi Furusho, Kenji Sakata and 35 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Cardiovascular research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Genes · 2024
    Article
  4. Article
  5. Review
  6. Significance of α-Myosin Heavy Chain (Journal of cardiovascular development and disease · 2022
    Article
  7. Article
  8. Review
  9. Functional Verification of NovelFrontiers in cell and developmental biology · 2021
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 10 institutions in 3 countries.

Kenshi HayashiDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Ryota TeramotoDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Akihiro NomuraDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Yoshihiro AsanoDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Manu BeerensDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Yasutaka KurataDepartment of Physiology, Kanazawa Medical University, Uchinada, Japan.
Isao KobayashiFaculty of Biological Science and Technology, Institute of Science and Engineering, Kanazawa University, Kanazawa, Japan.
Noboru FujinoDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Hiroshi FurushoDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Kenji SakataDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Kenji OnoueCardiovascular Medicine, Nara Medical University, Kashihara, Japan.
David Y ChiangDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Tuomas O KiviniemiDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Eva BuysDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Patrick SipsDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Micah L BurchDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Yanbin ZhaoDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Amy E KellyDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Masanobu NamuraDepartment of Cardiology, Kanazawa Cardiovascular Hospital, Kanazawa, Japan.
Yoshihito KitaDepartment of Internal Medicine, Wajima Municipal Hospital, Wajima, Japan.
Taketsugu TsuchiyaTrans-catheter Cardiovascular Therapeutics, Kanazawa Medical University, Uchinada, Japan.
Bunji KakuDivision of Cardiovascular Medicine, Toyama Red Cross Hospital, Toyama, Japan.
Kotaro OeDivision of Internal Medicine, Saiseikai Kanazawa Hospital, Kanazawa, Japan.
Yuko TakedaDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Tetsuo KonnoDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Masaru InoueDepartment of Cardiology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
Takashi FujitaDivision of Cardiology, Kouseiren Takaoka Hospital, Takaoka, Japan.
Takeshi KatoDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Akira FunadaDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Hayato TadaDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Akihiko HodatsuDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Chiaki NakanishiDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Yuichiro SakamotoDivision of Cardiology, Toyohashi Heart Center, Toyohashi, Japan.
Toyonobu TsudaDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Yoji NagataDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Yoshihiro TanakaDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Hirofumi OkadaDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Keisuke UsudaDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Shihe CuiDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Yoshihiko SaitoCardiovascular Medicine, Nara Medical University, Kashihara, Japan.
Calum A MacRaeDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Seiji TakashimaDepartment of Medical Biochemistry, Osaka University Graduate School of Medicine, Suita, Japan.
Masakazu YamagishiDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Masa-Aki KawashiriDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Masayuki TakamuraDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Kanazawa University · JPBrigham and Women's Hospital · USKanazawa Hospital · JPKanazawa Medical University · JPNara Medical University · JPThe University of Osaka · JPIshikawa Prefectural Central Hospital · JPKouseiren Takaoka Hospital · JPToyohashi Heart Center · JPUwajima City Hospital · JP

Funding

Partners Healthcare Training Program in Precision and Genomic MedicineT32HG010464 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI HEIDI L REHM, JORDAN W SMOLLER · 2019 to 2026
$3.1M
NHGRI NIH HHS T32 HG010464
6 · The paper itself

Abstract

aimsThe genetic cause of cardiac conduction system disease (CCSD) has not been fully elucidated. Whole-exome sequencing (WES) can detect various genetic variants; however, the identification of pathogenic variants remains a challenge. We aimed to identify pathogenic or likely pathogenic variants in CCSD patients by using WES and 2015 American College of Medical Genetics and Genomics (ACMG) standards and guidelines as well as evaluating the usefulness of functional studies for determining them. METHODS AND

resultsWe performed WES of 23 probands diagnosed with early-onset (<65 years) CCSD and analysed 117 genes linked to arrhythmogenic diseases or cardiomyopathies. We focused on rare variants (minor allele frequency < 0.1%) that were absent from population databases. Five probands had protein truncating variants in EMD and LMNA which were classified as 'pathogenic' by 2015 ACMG standards and guidelines. To evaluate the functional changes brought about by these variants, we generated a knock-out zebrafish with CRISPR-mediated insertions or deletions of the EMD or LMNA homologs in zebrafish. The mean heart rate and conduction velocities in the CRISPR/Cas9-injected embryos and F2 generation embryos with homozygous deletions were significantly decreased. Twenty-one variants of uncertain significance were identified in 11 probands. Cellular electrophysiological study and in vivo zebrafish cardiac assay showed that two variants in KCNH2 and SCN5A, four variants in SCN10A, and one variant in MYH6 damaged each gene, which resulted in the change of the clinical significance of them from 'Uncertain significance' to 'Likely pathogenic' in six probands.

conclusionOf 23 CCSD probands, we successfully identified pathogenic or likely pathogenic variants in 11 probands (48%). Functional analyses of a cellular electrophysiological study and in vivo zebrafish cardiac assay might be useful for determining the pathogenicity of rare variants in patients with CCSD. SCN10A may be one of the major genes responsible for CCSD.

Indexed as

Exome SequencingGenetic VariationAction PotentialsAdultAgedAge of OnsetAnimalsCardiac Conduction System DiseaseCase-Control StudiesComputer SimulationERG1 Potassium ChannelFemaleGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseHeart RateemerinERG1 Potassium ChannelKCNH2 protein, humanLamin Type ALMNA protein, humanMembrane ProteinsNAV1.5 Voltage-Gated Sodium ChannelNAV1.8 Voltage-Gated Sodium ChannelNuclear ProteinsSCN10A protein, humanSCN5A protein, humanZebrafish Proteins2015 ACMG standards and guidelinesCardiac conduction system diseaseCellular electrophysiological studyCRISPR/Cas9-mediated gene knock-out in zebrafishWhole exome sequencing

Identifiers

PMID31977013
PMCPMC8453299
OpenAlexW3001937884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.